Literature DB >> 10683849

Mood state and brain electric activity in ecstasy users.

A Gamma1, E Frei, D Lehmann, R D Pascual-Marqui, D Hell, F X Vollenweider.   

Abstract

Resting EEG during open and closed eyes and subsequent mood ratings were obtained from 15 Ecstasy users and 14 Ecstasy-naive controls. Absolute spectral power on the scalp, and the three-dimensional, intracerebral distribution of neuroelectric activity using low resolution brain electromagnetic tomography (LORETA) were computed. LORETA revealed global increases of theta, alpha 1 and beta 2/3 power during eyes open in Ecstasy users, and spectral analyses revealed a right-posterior increase of alpha 2 power (confirmed by LORETA) and increased beta band activity during open eyes. Ecstasy users had higher levels of state depressiveness, emotional excitability and a trend-level increase in state anxiety. The observed differences may be related to regular exposure to Ecstasy or other illicit drugs, or may be pre-existing.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10683849     DOI： 10.1097/00001756-200001170-00031

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  15 in total

1.  On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA.

Authors:  A Richard Green; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2002-08       Impact factor: 4.530

2.  Neurotoxicity and substance abuse: further fuel for regulatory dilemma.

Authors:  T Archer; T Palomo; R M Kostrzewa
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

3.  'Ecstasy' enhances noise-induced hearing loss.

Authors:  Michael W Church; Jinsheng S Zhang; Megan M Langford; Shane A Perrine
Journal:  Hear Res       Date:  2013-05-25       Impact factor: 3.208

4.  Electroencephalographic and convulsive effects of binge doses of (+)-methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4-methylenedioxymethamphetamine in rats.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Katherine D Holland; Charles V Vorhees; Michael T Williams
Journal:  Open Neuropsychopharmacol J       Date:  2012

5.  MDMA decreases glutamic acid decarboxylase (GAD) 67-immunoreactive neurons in the hippocampus and increases seizure susceptibility: Role for glutamate.

Authors:  Courtney L Huff; Rachel L Morano; James P Herman; Bryan K Yamamoto; Gary A Gudelsky
Journal:  Neurotoxicology       Date:  2016-10-20       Impact factor: 4.294

6.  Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats.

Authors:  Q David Walker; Christina N Williams; Rakesh P Jotwani; Samuel T Waller; Reynold Francis; Cynthia M Kuhn
Journal:  Psychopharmacology (Berl)       Date:  2006-09-23       Impact factor: 4.530

7.  Evidence of neurotoxicity of ecstasy: sustained effects on electroencephalographic activity in polydrug users.

Authors:  Michael Adamaszek; Alexander V Khaw; Ulrike Buck; Burghard Andresen; Rainer Thomasius
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

8.  Modifiable risk factors of ecstasy use: risk perception, current dependence, perceived control, and depression.

Authors:  Kit Sang Leung; Arbi Ben Abdallah; Jan Copeland; Linda B Cottler
Journal:  Addict Behav       Date:  2009-10-18       Impact factor: 3.913

9.  Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.

Authors:  Maartje M L de Win; Liesbeth Reneman; Johannes B Reitsma; Gerard J den Heeten; Jan Booij; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

10.  Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.

Authors:  Jörg Daumann; Gernot Hensen; Bastian Thimm; Markus Rezk; Bianca Till; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2004-01-14       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.